ClinicalTrials.gg
Active, not recruitingNCT06025578Updated Apr 23, 2026

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

A Phase 3 interventional study of BMS-986278 and BMS-986278 Placebo in Progressive Pulmonary Fibrosis, sponsored by Bristol-Myers Squibb. Active, not recruiting at 459 sites in 35 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,057
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 128 studies in Pulmonary Fibrosis with a site in United States — 30 open to participants now, 42 under way, 5 of them phase 3. Pulmonary Fibrosis · United States.

Planned enrollment
4th of 90
1,057 · median 50
Started
2023
with 5 others
Phase 3
15 of 128
2 open now
Primary completion
2027-12
later than 21 of 38 live
Registered
113th of 128
by date
Lead sponsor
4 of 128
Bristol-Myers Squibb

Among the 128 studies in Pulmonary Fibrosis with a site in United States, this one is the 4th largest by planned enrollment of the 90 interventional ones that give a count, is one of 6 that started in 2023, is one of 15 in phase 3, reaches primary completion later than 21 of the 38 other live ones, and was the 113th registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

30 of the 128 studies in Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

03

Conditions studied

  • Progressive Pulmonary Fibrosis

Keywords

  • BMS-986278
  • LPA1 antagonist
  • Pulmonary fibrosis
  • Interstitial lung disease
  • Rheumatoid Arthritis
  • Connective Tissue Disorders
  • Sarcoidosis
  • Scleroderma
  • Fibrosis
  • Antifibrotic therapy
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of interstitial lung disease (ILD) with features consistent with progressive ILD within 24 months prior to screening, and ≥ 10% extent of fibrosis on screening high-resolution computed tomography (HRCT).
  • If on pirfenidone or nintedanib, participants must have been on a stable dose for at least 90 days prior to screening.
  • If not currently on pirfenidone or nintedanib, participants must not have received either of these medications within 28 days prior to screening.
  • Mycophenolate mofetil (MMF), mycophenolic acid (MA), azathioprine (AZA), and Tacrolimus are permitted provided that the participant is on a stable dose for at least 90 days prior to screening. If not currently on MMF, MA, AZA, or tacrolimus, participants must not have taken these medications within 28 days prior to screening.
  • Traditional disease-modifying antirheumatic drug (DMARDs) (eg. Methotrexate, leflunomide, sulfasalazine, or hydroxychloroquine) are permitted provided that the participant is on a stable dose for at least 90 days prior to screening. If not currently on traditional DMARD, participants must not have taken these medications within 28 days prior to screening.
  • Biologic DMARDs (eg. TNF blockers and IL-1 inhibitors) and Janus kinase inhibitors (JAK inhibitors eg. tofacitinib, upadacitinib) are permitted provided that the participant is on a stable dose for at least 90 days prior to screening. If not currently on Biologic DMARD or JAK inhibitor, participants must not have taken these medications within 28 days prior to screening.
  • Women who are of must have a highly effective form of and must provide a negative urine/serum pregnancy test.
  • Men who are sexually active with women of childbearing potential agree to use male barrier contraception.

Exclusion criteria

Exclusion Criteria

  • Idiopathic pulmonary fibrosis with usual interstitial pneumonia (UIP) verification at screening.
  • History of stroke or within 3 months prior to screening.
  • Participants who exhibit symptoms of heart failure at rest.
  • Participants who have a current ; a previous malignancy with less than 2 years free of recurrence; and a that is suspicious for malignancy and the possibility of malignancy cannot be reasonably excluded following additional clinical, laboratory, or other diagnostic evaluations.
  • Use of systemic equivalent to prednisone > 15 mg/day is not allowed within 4 weeks prior to screening and during the study.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,057 participants (estimated)

Study arms

  • Experimental
    BMS-986278 Dose 1

    Drug: BMS-986278

  • Experimental
    BMS-986278 Dose 2

    Drug: BMS-986278

  • Placebo comparator
    BMS-986278 Placebo

    Drug: BMS-986278 Placebo

Interventions

  • Specified dose on specified days

  • DrugBMS-986278 Placebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Number of participants that experience spontaneous syncopal events

    Cohort 1

    Time frame: At approximately 4 weeks

  2. Absolute change from baseline in forced vital capacity (FVC) measured in mL

    Cohort 2

    Time frame: At Week 52

Secondary outcomes

  1. Number of participants who discontinued treatment due to any low BP-related Adverse Events

    Cohort 1

    Time frame: Up to approximately 3 years

  2. Disease progression

    Cohort 2 Disease progression will be measured by the time to first disease progression event in at least 1 of the following parameters: * Absolute percent predicted forced vital capacity (ppFVC) decline of ≥ 10% from baseline * Acute exacerbation of pulmonary fibrosis * Respiratory-related hospitalization * All-cause mortality

    Time frame: Up to approximately 3 years

  3. Change from baseline in Living with Pulmonary Fibrosis Questionnaire (L-PF) cough domain score

    Cohort 2

    Time frame: At Week 52 and up to approximately 3 years

  4. Change from baseline in L-PF dyspnea domain score

    Cohort 2

    Time frame: At Week 52 and up to approximately 3 years

  5. Change from baseline in walking distance measured in 6-minute walk test (6MWT)

    Cohort 2

    Time frame: At Week 52

  6. Time to the first occurrence of any of the components of the composite endpoint: time to first acute exacerbation of pulmonary fibrosis, first respiratory-related hospitalization, or all-cause mortality

    Cohort 2

    Time frame: Up to approximately 3 years

  7. Time to absolute percent ppFVC decline of ≥ 10% from baseline

    Cohort 2

    Time frame: Up to approximately 3 years

  8. Time to first acute exacerbation of pulmonary fibrosis

    Cohort 2

    Time frame: Up to approximately 3 years

  9. Time to first respiratory-related hospitalization

    Cohort 2

    Time frame: Up to approximately 3 years

  10. Time to first pulmonary fibrosis-related hospitalization.

    Cohort 2

    Time frame: Up to approximately 3 years

  11. Time to all-cause mortality

    Cohort 2

    Time frame: Up to approximately 3 years

  12. Change from baseline in L-PF fatigue domain score

    Cohort 2

    Time frame: At Week 52 and up to approximately 3 years

  13. Change from baseline in L-PF impacts module score

    Cohort 2

    Time frame: At Week 52 and up to approximately 3 years

  14. Change from baseline in cough numeric rating scale (NRS)

    Cohort 2

    Time frame: At Week 52 and up to approximately 3 years

  15. Change from baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) health utility index score

    Cohort 2

    Time frame: At Week 52

  16. Change from baseline in EQ-5D-5L visual analog scale score

    Cohort 2

    Time frame: At Week 52

  17. Rate of decline from baseline in FVC (mL)

    Cohort 2

    Time frame: At Week 52

  18. Rate of decline in ppFVC from baseline

    Cohort 2

    Time frame: At Week 52

  19. Change in ppFVC from baseline

    Cohort 2

    Time frame: At Week 52

  20. Proportion of participants with absolute decline in ppFVC ≥10%

    Cohort 2

    Time frame: At Week 52

  21. Proportion of participants with relative decline in ppFVC ≥10%

    Cohort 2

    Time frame: At Week 52

  22. Change from baseline in single-breath diffusing capacity of the lung for carbon monoxide (DLCO SB) (corrected for hemoglobin) (mL/min/mm Hg)

    Cohort 2

    Time frame: At Week 52

  23. Change in percent predicted single breath diffusing capacity of the lung for carbon monoxide (ppDLCO SB) (corrected for hemoglobin) from baseline

    Cohort 2

    Time frame: At Week 52

  24. Change from baseline in quantitative lung fibrosis (QLF) score via high-resolution computed tomography (HRCT)

    Cohort 2

    Time frame: At Week 52

  25. Number of participants with Adverse Events (AEs)

    Cohort 2

    Time frame: Up to 28 days after last dose

  26. Number of participants with Serious AEs (SAEs)

    Cohort 2

    Time frame: Up to 28 days after last dose

  27. Number of participants with AEs leading to early discontinuation of investigational medicinal product (IMP)

    Cohort 2

    Time frame: Up to 28 days after last dose

  28. Number of participants with AEs related to IMP

    Cohort 2

    Time frame: Up to 28 days after last dose

  29. Number of treatment-emergent deaths

    Cohort 2

    Time frame: Up to 28 days after last dose

  30. Number of participants with clinical laboratory abnormalities

    Cohort 2

    Time frame: Up to 28 days after last dose

  31. Number of participants with electrocardiogram (ECG) abnormalities

    Cohort 2

    Time frame: Up to 28 days after last dose

  32. Number of participants with vital sign abnormalities

    Cohort 2

    Time frame: Up to 28 days after last dose

07

Study locations

459 sites
  • Local Institution - 0046
    Birmingham, Alabama 35294, United States
  • Local Institution - 0314
    Phoenix, Arizona 85013-4220, United States
  • Local Institution - 0336
    La Jolla, California 92037-1027, United States
  • Local Institution - 0212
    Los Angeles, California 90033-5313, United States
  • Local Institution - 0019
    Los Angeles, California 90095-3075, United States
  • Local Institution - 0535
    Newport Beach, California 92663-3661, United States
  • Local Institution - 0366
    Orange, California 92868-3201, United States
  • Local Institution - 0341
    Sacramento, California 95817, United States
  • Local Institution - 0015
    San Francisco, California 94143-2202, United States
  • Local Institution - 0352
    Stanford, California 94305, United States
  • Local Institution - 0321
    Aurora, Colorado 80045, United States
  • Local Institution - 0376
    Denver, Colorado 80206, United States
  • Local Institution - 0211
    New Haven, Connecticut 06510, United States
  • Local Institution - 0418
    Stamford, Connecticut 06904, United States
  • Local Institution - 0067
    Newark, Delaware 19713-1337, United States
  • Local Institution - 0354
    Washington D.C., District of Columbia 20007-2113, United States
  • Local Institution - 0195
    Brandon, Florida 33511-5706, United States
  • Local Institution - 0380
    Celebration, Florida 34747-1818, United States
  • Local Institution - 0013
    Clearwater, Florida 33765, United States
  • Local Institution - 0396
    DeBary, Florida 32713-1817, United States
  • Local Institution - 0036
    Gainesville, Florida 32608, United States
  • Local Institution - 0193
    Gainesville, Florida 32610, United States
  • Local Institution - 0073
    Loxahatchee Groves, Florida 33411, United States
  • Local Institution - 0220
    Ocala, Florida 34470, United States
  • Local Institution - 0452
    Pensacola, Florida 32503, United States
  • Local Institution - 0389
    St. Petersburg, Florida 33704, United States
  • Local Institution - 0316
    Tampa, Florida 33601-1289, United States
  • Local Institution - 0070
    Atlanta, Georgia 30322-1013, United States
  • Local Institution - 0368
    Dublin, Georgia 31021-2561, United States
  • Local Institution - 0435
    Chicago, Illinois 60611, United States
  • Local Institution - 0023
    Chicago, Illinois 60637-1447, United States
  • Local Institution - 0040
    Evanston, Illinois 60201-1779, United States
  • Local Institution - 0082
    Maywood, Illinois 60153-3328, United States
  • Local Institution - 0080
    Iowa City, Iowa 522242-1009, United States
  • Local Institution - 0049
    Kansas City, Kansas 66103-2937, United States
  • Local Institution - 0045
    Louisville, Kentucky 40207-4652, United States
  • Local Institution - 0361
    Louisville, Kentucky 40218-2497, United States
  • Local Institution - 0305
    Baltimore, Maryland 21201-1544, United States
  • Local Institution - 0033
    Towson, Maryland 21204-7700, United States
  • Local Institution - 0404
    Boston, Massachusetts 02114-2621, United States
  • Local Institution - 0079
    Springfield, Massachusetts 01199-1002, United States
  • Local Institution - 0207
    Ann Arbor, Michigan 48109-5000, United States
  • Local Institution - 0031
    Detroit, Michigan 48202, United States
  • Local Institution - 0050
    Grand Rapids, Michigan 49546-8293, United States
  • Local Institution - 0509
    Royal Oak, Michigan 48073-6712, United States
  • Local Institution - 0384
    Minneapolis, Minnesota 55455-4800, United States
  • Local Institution - 0004
    Chesterfield, Missouri 63017, United States
  • Local Institution - 0223
    St Louis, Missouri 63110-1010, United States
  • Local Institution - 0525
    Reno, Nevada 89502-1576, United States
  • Local Institution - 0068
    Mount Kisco, New York 10549-3417, United States
  • Local Institution - 0357
    New York, New York 10029-6574, United States
  • Local Institution - 0428
    Durham, North Carolina 27710, United States
  • Local Institution - 0392
    Wilmington, North Carolina 28401-7307, United States
  • Local Institution - 0325
    Winston-Salem, North Carolina 27103, United States
  • Local Institution - 0419
    Cincinnati, Ohio 45267, United States
  • Local Institution - 0186
    Cleveland, Ohio 44106, United States
  • Local Institution - 0209
    Columbus, Ohio 43201, United States
  • Local Institution - 0343
    Toledo, Ohio 43608-2603, United States
  • Local Institution - 0198
    Oklahoma City, Oklahoma 73104-5417, United States
  • Local Institution - 0008
    Tulsa, Oklahoma 74133, United States
  • Local Institution - 0037
    Portland, Oregon 97239-3011, United States
  • Local Institution - 0205
    Hershey, Pennsylvania 17033-2360, United States
  • Local Institution - 0334
    Philadelphia, Pennsylvania 19104-5161, United States
  • Local Institution - 0348
    Philadelphia, Pennsylvania 19107-5109, United States
  • Local Institution - 0196
    Philadelphia, Pennsylvania 19140-5103, United States
  • Local Institution - 0364
    Wynnewood, Pennsylvania 19096, United States
  • Local Institution - 0531
    Anderson, South Carolina 29621, United States
  • Local Institution - 0071
    Charleston, South Carolina 29425, United States
  • Local Institution - 0373
    Greenville, South Carolina 29615, United States
  • Local Institution - 0363
    Nashville, Tennessee 37204, United States
  • Local Institution - 0024
    Dallas, Texas 75235-5351, United States
  • Local Institution - 0317
    Dallas, Texas 75246, United States
  • Local Institution - 0028
    Houston, Texas 77030-4202, United States
  • Local Institution - 0041
    Houston, Texas 77030, United States
  • Local Institution - 0221
    McKinney, Texas 75069, United States
  • Local Institution - 0217
    San Antonio, Texas 78229-4404, United States
  • Local Institution - 0014
    Salt Lake City, Utah 84108, United States
  • Local Institution - 0504
    Burlington, Vermont 05401, United States
  • Local Institution - 0414
    Richmond, Virginia 23298-5002, United States
  • Local Institution - 0190
    Everett, Washington 98208-6526, United States
  • Local Institution - 0043
    Seattle, Washington 98195, United States
  • Local Institution - 0020
    Mar del Plata, Buenos Aires 7600, Argentina
  • Local Institution - 0446
    San Juan Bautista, Buenos Aires 1888, Argentina
  • Local Institution - 0025
    Buenos Aires, B C1426ABO, Argentina
  • Local Institution - 0039
    Caba, B C1425FVH, Argentina
  • Local Institution - 0003
    Florida, B 1602, Argentina
  • Local Institution - 0182
    Mar del Plata, B 7600, Argentina
  • Local Institution - 0501
    Quilmes, Provincia de Buenos Aires, B 1878, Argentina
  • Local Institution - 0162
    Ciudad Autónoma Buenos Aires, C 1181, Argentina
  • Local Institution - 0032
    Córdoba, Córdoba Province K5003DCE, Argentina
  • Local Institution - 0288
    Godoy Cruz, M 5501, Argentina
  • Local Institution - 0401
    Mendoza, M M5500, Argentina
  • Local Institution - 0400
    Rosario, S 2000, Argentina
  • Local Institution - 0005
    San Miguel de Tucuman, Tucumán, T T4000, Argentina
  • Local Institution - 0165
    Buenos Aires, C1056ABJ, Argentina
  • Local Institution - 0450
    Santa Fe, 3000, Argentina
  • Local Institution - 0065
    Camperdown, New South Wales 2050, Australia
  • Local Institution - 0089
    Westmead, New South Wales 2145, Australia
  • Local Institution - 0090
    Brisbane, Queensland 4032, Australia
  • Local Institution - 0091
    Greenslopes, Queensland 4120, Australia

Showing the first 100 of 459 sites across 35 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Dec 2027, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2023
First posted
Sep 6, 2023
StartActual
Oct 25, 2023
Primary completionEst.
Dec 27, 2027
CompletionEst.
Dec 27, 2027
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06025578
Responsible party
Sponsor
First posted
Sep 6, 2023
Start date
Oct 25, 2023
Primary completion
Dec 27, 2027 (estimated)
Completion
Dec 27, 2027 (estimated)
Last update
Apr 23, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Admilparant

Start the discussion